Press Releases

Home / Investor Relations / Press Releases

Language

Category

Year

2026-02-06 10:30 Boule Diagnostics – Invitation to presentation of the Q4 report 2025

Boule Diagnostics AB will publish the year-end report for 2025 at 08:00, Wednesday, February 11, 2026. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors. CEO Torben Nielsen and CFO Holger Lembrér will present...

2026-01-21 08:30 Boule Diagnostics Renews and Expands a Global Supply Agreement

Clinical Diagnostics Solutions (CDS), a Boule Diagnostics company in the US, announces that its supply agreement with a leading global In Vitro Diagnostics (IVD) customer has been renewed and expanded. The extended agreement is a result of the trust in...

2025-12-30 08:30 Boule Diagnostics appoints Michael af Winklerfelt as new CFO Regulatory

Boule Diagnostics AB appoints Michael af Winklerfelt as new CFO, effective February 2026. Michael af Winklerfelt brings extensive international experience from senior finance roles in pharmaceuticals, medical technology, and industrial sectors. He has...

2025-12-22 11:00 Boule Diagnostics Selected as One of Three Providers in Nationwide Hematology Tender in Italy

Boule Diagnostics, together with its Italian distribution partner A. Menarini Diagnostics, is proud to announce its selection as one of only three providers in a nationwide tender for hematology solutions in Italy. The tender decision, finalized on November...

2025-12-05 08:25 Boule Diagnostics Announces CEO Transition as Organization Prepares for Next Chapter Regulatory

Boule Diagnostics today announced that Torben Nielsen, Chief Executive Officer, has decided to leave the company to pursue another professional opportunity. Under Torben’s leadership, the company has undergone a significant restructure, achieved positive...

2025-11-21 16:00 Boule Diagnostics – Nomination Committee for the Annual General Meeting 2026 Regulatory

The 2025 Annual General Meeting of Boule Diagnostics AB (publ), ("Boule"), resolved that a Nomination Committee based on the ownership structure on 30 September 2025 shall be appointed to propose the Annual General Meeting 2026: 1. Proposal for Chairman...

2025-10-24 08:00 Boule Diagnostics Interim Report Q3 2025 Regulatory

Back to organic growth Quarter July-September 2025 Comments from the President and CEO Back to organic growth In the third quarter, we returned to organic growth in a market that continues to face structural challenges. However, we are starting to...

2025-10-20 10:45 Boule Diagnostics – Invitation to presentation of the interim report Q3 2025

Boule Diagnostics AB will publish the interim report for the period July-September 2025 at 08:00, Friday, October 24, 2025. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors. CEO Torben Nielsen and CFO Holger...

2025-10-13 08:35 Boule Diagnostics Announces CFO Departure for New Opportunity Regulatory

Boule Diagnostics today announced that Holger Lembrér, Chief Financial Officer, will be leaving the company to pursue a new professional opportunity outside the organization. Torben Nielsen, CEO of Boule Diagnostics, commented: "We are grateful for Holger’s...

2025-07-18 08:00 Boule Diagnostics Interim Report Q2 2025 Regulatory

Strong instrument sales Quarter April-June 2025 Comments from the President and CEO Strong instrument sales in continued challenging market conditions The second quarter of the year saw the continued effects of the geopolitical instability with longer...

2025-07-11 11:00 Boule Diagnostics – Invitation to presentation of the interim report Q2 2025

Boule Diagnostics AB will publish the interim report for the period April-June 2025 at 08:00, Friday, July 18, 2025. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors. CEO Torben Nielsen and CFO Holger Lembrér...

2025-05-07 17:45 Bulletin from the Annual General Meeting May 7, 2025 in Boule Diagnostics Regulatory

At the Annual General Meeting 2025 (the “AGM”) it was resolved to adopt the profit and loss statement and the balance sheet and the consolidated profit and loss statement and the consolidated balance sheet. The AGM resolved to approve that the company’s...

2025-04-28 08:00 Boule Diagnostics Interim Report Q1 2025 Regulatory

Transformative quarter

2025-04-23 13:00 Boule Diagnostics – Invitation to presentation of the interim report Q1 2025

Boule Diagnostics AB will publish the interim report for the period January–March 2025 at 08:00, Monday, April 28th, 2025. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors. CEO Torben Nielsen and CFO Holger...

2025-01-31 15:10 Boule Diagnostics – Invitation to presentation of the year-end report 2024

Boule Diagnostics AB will publish the year-end report for the period January–December 2024 at 08:00, Tuesday, February 11th, 2025. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors. CEO Torben Nielsen and...

2024-10-25 08:00 Boule Diagnostics interim report Q3 2024 Regulatory

Strong improvement in profitability Quarter July - September 2024 Comments by the CEO Torben Nielsen Strong improvement in profitability Sales in Q3 reached SEK 130M and declined organically by 2%, currency impacted with -4,6%. Reagents sales declined...

2024-10-18 16:00 Boule Diagnostics – Invitation to presentation of the interim report Q3 2024

Boule Diagnostics AB will publish the interim report for the period January–September 2024 at 08:00, Friday, October 25th, 2024. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors. CEO Torben Nielsen and CFO...

2024-10-16 15:00 Boule Diagnostics – Nomination Committee for the Annual General Meeting 2025

The 2024 Annual General Meeting of Boule Diagnostics AB (publ), ("Boule"), resolved that a Nomination Committee based on the ownership structure on 30 September 2024 shall be appointed to propose the Annual General Meeting 2025: Boule's largest shareholders...

2024-10-08 08:30 Boule Diagnostics reports one-off costs in third quarter earnings Regulatory

Boule Diagnostics reports a one-off non-cash cost of SEK 265 M in the third quarter, related to the development project of the technology platform BM900. The one-off cost is attributable to an impairment of intangible assets capitalized for the technology...

2024-07-22 07:30 Boule Diagnostics interim report Q2 2024 Regulatory

Stable development and improved margins Quarter April - June 2024 Comments by the CEO Torben Nielsen Q2 focused on cost optimization In line with our strategic priorities, we launched a restructuring program in Q2 with the aim of reducing both production...